Recombinant Human Fumarylacetoacetase/FAH Protein，His

Fumarylacetoacetase (FAH) is a crucial enzyme in the tyrosine catabolism pathway, playing a vital role in the conversion of fumarylacetoacetate to acetoacetate and fumarate. Deficiency in FAH leads to a rare genetic disorder known as hereditary tyrosinemia type I (HT1), characterized by severe liver dysfunction, renal failure, and neurological complications. The accumulation of toxic metabolites in HT1 patients necessitates the development of effective therapeutic strategies. Research on recombinant FAH has gained significant attention as a potential treatment option. By expressing FAH in various host systems, such as bacteria or mammalian cells, scientists aim to produce functional enzyme that can be used for enzyme replacement therapy (ERT) or in cell-based therapies. Advances in protein engineering and purification techniques have improved the yield and activity of recombinant FAH, making it a promising candidate for clinical applications. Moreover, ongoing studies focus on understanding the enzyme's structure-function relationship, which may provide insights into the design of small molecule drugs or gene therapies that could enhance FAH activity in patients. The successful development of recombinant FAH could significantly improve the quality of life for individuals with HT1 and pave the way for innovative treatments for other metabolic disorders.